deferasirox has been researched along with Leukemia in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Q; Gu, J; Li, N; Li, S; Wang, W; Wang, X; Wang, Z; Zhao, G | 1 |
| Agriesti, F; Capitanio, N; De Luca, L; Della Sala, G; Laurenzana, I; Mazzoccoli, C; Musto, P; Pacelli, C; Piccoli, C; Ruggieri, V; Simeon, V; Tataranni, T | 1 |
| Imanishi, S; Ohsuga, M; Ohyashiki, JH; Ohyashiki, K; Takahashi, R | 1 |
| Chang, YC; Cheng, HC; Feng, CC; Huang, YT; Lin, CL; Lin, HT; Lo, WJ; Yeh, SP | 1 |
| Alberti, D; Arruga, F; Bracco, E; Carturan, S; Cilloni, D; Defilippi, I; Greco, E; Maffè, C; Messa, E; Messa, F; Pautasso, M; Pellegrino, RM; Roetto, A; Rosso, V; Rotolo, A; Saglio, G; Zanone, C | 1 |
| Bahcebasi, S; Cetin, M; Deniz, K; Eser, B; Kaynar, L; Kurnaz, F; Ozturk, A; Pala, C; Sivgin, S; Unal, A; Uzer, E | 1 |
6 other study(ies) available for deferasirox and Leukemia
| Article | Year |
|---|---|
Synergistic inhibitory effects of deferasirox in combination with decitabine on leukemia cell lines SKM-1, THP-1, and K-562.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Benzoates; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Decitabine; Deferasirox; Drug Synergism; Gene Expression Regulation; Humans; Iron Chelating Agents; Leukemia; Reactive Oxygen Species; Triazoles | 2017 |
Deferasirox drives ROS-mediated differentiation and induces interferon-stimulated gene expression in human healthy haematopoietic stem/progenitor cells and in leukemia cells.
Topics: Blotting, Western; Cell Differentiation; Cell Line; Deferasirox; Gene Expression; Hematopoietic Stem Cells; HL-60 Cells; Humans; Interferons; Leukemia; Mitochondria; Phosphorylation; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Signal Transduction; STAT1 Transcription Factor | 2019 |
Effect of combined deferasirox and 5-azacytidine treatment on human leukemia cells in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzoates; Deferasirox; HL-60 Cells; Humans; Iron Chelating Agents; Leukemia; Triazoles; U937 Cells | 2015 |
Deferasirox has strong anti-leukemia activity but may antagonize theanti-leukemia effect of doxorubicin.
Topics: Antineoplastic Agents; Apoptosis; Benzoates; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deferasirox; Doxorubicin; Extracellular Signal-Regulated MAP Kinases; Humans; Iron; Leukemia; Phosphorylation; Reactive Oxygen Species; Triazoles | 2017 |
Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging.
Topics: Aged; Aged, 80 and over; Apoptosis; Benzoates; Blotting, Western; Deferasirox; Electrophoretic Mobility Shift Assay; Female; Flow Cytometry; Fluorescent Antibody Technique; Humans; Iron; Iron Chelating Agents; K562 Cells; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; NF-kappa B; Protein Binding; Reactive Oxygen Species; Triazoles | 2010 |
Efficacy and safety of oral deferasirox treatment in the posttransplant period for patients who have undergone allogeneic hematopoietic stem cell transplantation (alloHSCT).
Topics: Adolescent; Adult; Benzoates; Deferasirox; Female; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Iron Overload; Kidney; Leukemia; Leukemia, Myeloid, Acute; Liver; Male; Middle Aged; Phlebotomy; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Homologous; Triazoles; Young Adult | 2012 |